Sign inCreate account

Report workspace tools

NCT06433557ACTIVE_NOT_RECRUITINGanonymous

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Sponsor

Source record

Ascendis Pharma Growth Disorders A/S

Phase

Source record

PHASE2

Modality

AI-normalized

combination therapy

Target

AI-normalized

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Source & freshness

Source record

NCT ID

NCT06433557

Original source

ClinicalTrials.gov

Source last updated

Feb 18, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06433557

Title

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Sponsor

Ascendis Pharma Growth Disorders A/S

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE2

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

combination therapy

Modality normalized

combination therapy

Target raw

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Target normalized

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Interventions

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Public preview

Source record

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06433557

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE2

Sponsor

Ascendis Pharma Growth Disorders A/S

Executive brief

Investment-Ready Snapshot

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 18, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06433557

Indication

Achondroplasia

Modality

combination therapy

Target

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Intervention

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.